Cell Division Cycle 34 homolog Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Cell Division Cycle 34 homolog antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Cell Division Cycle 34 homolog |
| Clone | [CPTC-CDC34-2] |
| Host Species | Mouse |
| Reactive Species | human. |
| Isotype | IgG1 |
| Format | purified |
| Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
| Concentration | n/a |
| Applications | Immunohistology (Formalin-Fixed) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: Cell cycle events are regulated by the sequential activation and deactivation of cyclin dependent kinases (Cdks) and by the proteolysis of cyclins. The cell division cycle (Cdc) genes are required at various points in the cell cycle. Cdc25A, Cdc25B and Cdc25C protein tyrosine phosphatases function as mitotic activators by dephosphorylating Cdc2 p34 on regulatory tyrosine residues. Cdc6 is the human homolog of Saccharomyces cerevisiae Cdc6, which is involved in the initiation of DNA replication. Cdc37 appears to facilitate Cdk4/cyclin D1 complex formation and has been shown to form a stable complex with HSP 90. Cdc34, Cdc27 and Cdc16 function as ubiquitinconjugating enzymes. Cdc34 is thought to be the structural and functional h |
| Immunogen | Immunogen: Recombinant human full-length CDC34protein Positive Control: 293, K562, Jurkat cell lysates. Human small intestine. |
| Other Names | [Cdc34; cell division cycle 34; UBC3; UBCH3; UBE2R1; Ubiquitin carrier protein; Ubiquitin conjugating enzyme E2 32 kDa complementing; Ubiquitin protein ligase R1; Ubiquitin conjugating enzyme E2-CDC34] |
| Gene, Accession # | [CDC34], Gene ID: 997, NCBI: NP_004350.1, UniProt: P49427 |
| Catalog # | MBS4380753 |
| Price | $190, $340, $340 |
| Order / More Info | Cell Division Cycle 34 homolog Antibody from MYBIOSOURCE INC. |
| Product Specific References | Zhai, Y., et al. 1999. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 13: 181-189.; Zhai, Y., et al. 1999. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int. J. Cancer 82: 131-136. 5.; Parr C, Gan CH, Watkins G, Jiang WG. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis. 2006; 9(2):73-81. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies